2.40
price up icon0.42%   0.010
after-market Handel nachbörslich: 2.38 -0.02 -0.83%
loading
Schlusskurs vom Vortag:
$2.39
Offen:
$2.4
24-Stunden-Volumen:
50,014
Relative Volume:
0.34
Marktkapitalisierung:
$40.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-6.25%
1M Leistung:
-5.14%
6M Leistung:
-72.09%
1J Leistung:
+0.00%
1-Tages-Spanne:
Value
$2.37
$2.4356
1-Wochen-Bereich:
Value
$2.35
$2.698
52-Wochen-Spanne:
Value
$1.70
$19.40

Onkure Therapeutics Inc Stock (OKUR) Company Profile

Name
Firmenname
Onkure Therapeutics Inc
Name
Telefon
(720) 307-2892
Name
Adresse
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Name
Mitarbeiter
46
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
OKUR's Discussions on Twitter

Vergleichen Sie OKUR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
OKUR
Onkure Therapeutics Inc
2.40 40.40M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-30 Eingeleitet Evercore ISI Outperform
2024-12-05 Eingeleitet Leerink Partners Outperform
2024-10-10 Eingeleitet Oppenheimer Outperform
2023-12-15 Herabstufung H.C. Wainwright Buy → Neutral
2023-12-15 Herabstufung Jefferies Buy → Hold
2023-12-15 Herabstufung Leerink Partners Outperform → Market Perform
2023-12-14 Herabstufung BofA Securities Buy → Underperform
2023-12-14 Herabstufung Ladenburg Thalmann Buy → Neutral
2023-12-14 Herabstufung Piper Sandler Overweight → Neutral
2023-12-14 Herabstufung Robert W. Baird Outperform → Neutral
2023-12-14 Herabstufung William Blair Outperform → Mkt Perform
2023-11-15 Eingeleitet William Blair Outperform
2023-08-28 Eingeleitet H.C. Wainwright Buy
2023-07-03 Eingeleitet BofA Securities Buy
2022-09-19 Fortgesetzt H.C. Wainwright Buy
2022-01-27 Eingeleitet Robert W. Baird Outperform
2021-12-21 Eingeleitet H.C. Wainwright Buy
2021-11-22 Eingeleitet Ladenburg Thalmann Buy
2021-05-04 Eingeleitet Jefferies Buy
2021-05-04 Eingeleitet Piper Sandler Overweight
2021-05-04 Eingeleitet SVB Leerink Outperform
Alle ansehen

Onkure Therapeutics Inc Aktie (OKUR) Neueste Nachrichten

pulisher
Jun 08, 2025

Two Sigma Advisers LP Invests $122,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 08, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Purchases New Position in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Buy Rating for OnKure Therapeutics Driven by Promising Developments in Metastatic Breast Cancer Treatment and Strong Financial Position - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Bank of America Corp DE Takes $2.15 Million Position in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 03, 2025
pulisher
May 28, 2025

OnKure Elects Directors at Annual Stockholder Meeting - TipRanks

May 28, 2025
pulisher
May 25, 2025

OnKure Therapeutics (NASDAQ:OKUR) Given Consensus Recommendation of “Buy” by Analysts - Defense World

May 25, 2025
pulisher
May 19, 2025

Major Stakeholders Shuffle Shares in OnKure Therapeutics - TipRanks

May 19, 2025
pulisher
May 17, 2025

OnKure Therapeutics Inc (OKUR) At $2.00 Is Well Worth Your Time - Stocksregister

May 17, 2025
pulisher
May 15, 2025

Barclays PLC Purchases New Stake in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

May 15, 2025
pulisher
May 14, 2025

Major Shareholder Sells Thousands of OnKure Therapeutics Shares! - TipRanks

May 14, 2025
pulisher
May 10, 2025

Leerink Partnrs Issues Optimistic Outlook for OKUR Earnings - Defense World

May 10, 2025
pulisher
May 09, 2025

Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure Therapeutics - TipRanks

May 09, 2025
pulisher
May 07, 2025

OnKure increased R&D spending in 1Q with drug trials underway - BizWest

May 07, 2025
pulisher
May 07, 2025

OnKure Therapeutics Reports Q1 2025 Progress and Financials - TipRanks

May 07, 2025
pulisher
May 06, 2025

Form 424B3 OnKure Therapeutics, - StreetInsider

May 06, 2025
pulisher
May 06, 2025

OnKure Therapeutics Reports Progress in PIKture-01 Trial and Financial Results for Q1 2025 - Nasdaq

May 06, 2025
pulisher
May 06, 2025

OnKure Therapeutics, Inc. SEC 10-Q Report - TradingView

May 06, 2025
pulisher
May 06, 2025

OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

May 06, 2025
pulisher
May 06, 2025

Head to Head Contrast: OnKure Therapeutics (NASDAQ:OKUR) & Anebulo Pharmaceuticals (NASDAQ:ANEB) - Defense World

May 06, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Invests $408,000 in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

May 05, 2025
pulisher
May 04, 2025

OnKure Therapeutics (OKUR) Projected to Post Earnings on Tuesday - Defense World

May 04, 2025
pulisher
May 03, 2025

OnKure Therapeutics (NASDAQ:OKUR) Research Coverage Started at Evercore ISI - Defense World

May 03, 2025
pulisher
May 03, 2025

OnKure Therapeutics (NASDAQ:OKUR) Receives $32.33 Average Price Target from Brokerages - Defense World

May 03, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Makes New $659,000 Investment in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

May 02, 2025
pulisher
May 02, 2025

Q1 Earnings Estimate for OKUR Issued By Leerink Partnrs - Defense World

May 02, 2025
pulisher
Apr 30, 2025

OnKure Therapeutics initiated with an Outperform at Evercore ISI - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

Evercore ISI starts OnKure stock with Outperform rating - Investing.com

Apr 30, 2025
pulisher
Apr 30, 2025

Evercore ISI starts OnKure stock with Outperform rating By Investing.com - Investing.com India

Apr 30, 2025
pulisher
Apr 28, 2025

OKUR stock touches 52-week low at $2.49 amid market challenges - Investing.com

Apr 28, 2025
pulisher
Apr 10, 2025

OnKure Therapeutics CEO sells $2,569 in stock - Investing.com Australia

Apr 10, 2025
pulisher
Apr 08, 2025

OnKure Therapeutics CFO sells $9,177 in stock By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

OnKure Therapeutics CEO sells $2,569 in stock By Investing.com - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

OnKure Therapeutics CFO sells $9,177 in stock - Investing.com

Apr 08, 2025
pulisher
Apr 05, 2025

OKUR stock touches 52-week low at $3.39 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

OKUR stock touches 52-week low at $3.39 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Mar 29, 2025

We're Keeping An Eye On OnKure Therapeutics' (NASDAQ:OKUR) Cash Burn Rate - simplywall.st

Mar 29, 2025
pulisher
Mar 28, 2025

OKUR stock touches 52-week low at $4.43 amid market challenges - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

OKUR stock touches 52-week low at $4.43 amid market challenges By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 21, 2025

Q1 EPS Estimate for OnKure Therapeutics Lowered by Analyst - Defense World

Mar 21, 2025
pulisher
Mar 20, 2025

OnKure Therapeutics (OKUR) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 18, 2025

H.C. Wainwright cuts OnKure Therapeutics price target to $34 By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 18, 2025

Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright cuts OnKure Therapeutics price target to $34 - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025 - TipRanks

Mar 18, 2025
pulisher
Mar 16, 2025

Analyzing Organogenesis (NASDAQ:ORGO) and OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

OKUR stock touches 52-week low at $4.54 amid market challenges - Investing.com Australia

Mar 15, 2025

Finanzdaten der Onkure Therapeutics Inc-Aktie (OKUR)

Es liegen keine Finanzdaten für Onkure Therapeutics Inc (OKUR) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Onkure Therapeutics Inc-Aktie (OKUR) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Leverone Jason A.
Chief Financial Officer
Jun 23 '25
Sale
2.38
303
722
12,906
Cormorant Asset Management, LP
Former 10% Owner
May 15 '25
Sale
1.85
1,813,439
3,363,023
0
ACORN BIOVENTURES, L.P.
10% Owner
May 15 '25
Buy
1.85
1,129,730
2,090,000
1,129,730
ACORN BIOVENTURES, L.P.
10% Owner
May 15 '25
Buy
1.85
270,270
500,000
1,709,944
Cormorant Asset Management, LP
10% Owner
May 12 '25
Sale
1.99
24,300
48,236
1,813,439
Saccomano Nicholas A
President and CEO
Apr 07 '25
Sale
2.67
516
1,378
3,682
Saccomano Nicholas A
President and CEO
Apr 04 '25
Sale
3.33
358
1,191
4,198
Leverone Jason A.
Chief Financial Officer
Apr 07 '25
Sale
2.67
1,844
4,925
13,209
Leverone Jason A.
Chief Financial Officer
Apr 04 '25
Sale
3.33
1,278
4,253
15,053
Leonard Braden Michael
10% Owner
Sep 25 '24
Buy
1.50
68,746
102,872
3,457,395
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):